CompletedNCT00723606
A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation
Researchers compared Intramuscular ziprasidone mesylate and Intramuscular haloperidol, tracking side effects to assess safety and tolerability in people with schizophrenia.
Medication studyAges 18–65China
Understand this study
What did researchers investigate?
Researchers compared Intramuscular ziprasidone mesylate and Intramuscular haloperidol, tracking side effects to assess safety and tolerability in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Baoding and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateSeptember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 376
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00723606
- Official title
Show the full official title
A Randomized, Open Label, Rater Blind, Flexible Dose Multi-Center Study Comparing The Efficacy And Safety Of Intramuscular Ziprasidone With Haloperidol For Three Days In Patients With Agitation Of Schizophrenia
Recruitment & locations
CompletedBaoding · Wuhan · Kunming
5 more locations
- Beijing
- Changsha
- Guangzhou
- Nanjing
- Xi'an
Questions about this study
What did researchers investigate?
Researchers compared Intramuscular ziprasidone mesylate and Intramuscular haloperidol, tracking side effects to assess safety and tolerability in people with schizophrenia.
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Did this study involve medication?
Yes. The study involved medication, including Intramuscular ziprasidone mesylate and Intramuscular haloperidol.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit meRelated studies
5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolarity